Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) has elected Ms. Tracey C. Doi to its Board of Directors, increasing the board's membership to 10. As CFO of Toyota Motor North America, Ms. Doi brings extensive experience in finance and strategic planning. Company leadership expressed confidence that her expertise will enhance Quest's capabilities in the healthcare sector. Alongside her role at Quest, Ms. Doi is involved with various organizations, contributing to risk management and corporate governance initiatives.
Quest Diagnostics (DGX) has declared a quarterly cash dividend of $0.62 per share, to be paid on October 20, 2021. Shareholders of record as of October 5, 2021 will receive this dividend. The company, a leader in diagnostic information services, highlights its commitment to improving health outcomes through diagnostic insights. Quest services about one in three adult Americans and supports numerous healthcare providers across the U.S., employing nearly 50,000 staff dedicated to transforming lives through health management.
Quest Diagnostics (DGX) reported strong Q2 2021 results, with net revenues soaring to $2,550 million, a 39.5% increase year-over-year. This marks the first time since 2019 that organic base testing revenues grew, propelled by new hospital lab contracts and increased healthcare engagement. Operating income rose 88.4% to $533 million, resulting in a diluted EPS of $4.96, a 264.2% increase. The company anticipates 2021 net revenues between $9.54 billion and $9.79 billion and adjusted diluted EPS of $10.65 to $11.35.
CLX Health has partnered with Quest Diagnostics (NYSE: DGX) to enhance COVID-19 testing access for individuals attending live events or traveling internationally. This collaboration allows users to schedule PCR/NAAT tests at Quest's patient service centers and over 750 retail pharmacy locations across the U.S., with results available within 48 hours. Quest is the first national provider to join the TrustAssure™ Global Testing Platform, which coordinates testing locations for major airlines and event venues. This initiative aims to facilitate safer travel experiences as pandemic restrictions ease.
Summary not available.
Quest Diagnostics (DGX) has launched the Tackle Your Testing program to combat health disparities worsened by the COVID-19 pandemic. The initiative aims to provide no-cost diagnostic testing services at events starting from July 17-18 in Tampa, Florida, in collaboration with local health centers and charities. This program addresses the decline in routine diagnoses of chronic illnesses during the pandemic, offering consultations, educational resources, and healthy meals. Former NFL player Warrick Dunn will also participate in promoting this health initiative.
Quest Diagnostics (NYSE: DGX) has announced it will release its second quarter 2021 financial results on July 22, 2021, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss these results. Interested participants can access the call through various numbers provided for U.S., Canada, and international callers. A replay will be available shortly after the call. Quest Diagnostics continues to provide diagnostic insights, serving a substantial portion of American adults and healthcare providers.
Biocept, Inc. (Nasdaq: BIOC) announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide its Target Selector NGS-based liquid biopsy assay for lung cancer testing. This assay, designed for patients with advanced non-small cell lung cancer, enables less invasive genomic profiling and monitoring of treatment effectiveness. Expected to launch in Q4 2021, the service will be accessible through Quest's extensive patient service centers across the U.S. This partnership aims to enhance patient care and expand Biocept’s market reach in oncology diagnostics.
Quest Diagnostics (NYSE: DGX) released its 2020 Annual Corporate Responsibility Report, titled "A Year of Challenge and Change." The report highlights the company's response to the COVID-19 pandemic, including performing 30 million tests and launching the Quest for Health Equity initiative, aimed at reducing health disparities in underserved communities with over $100 million allocated for this purpose. Additionally, Quest made strides in operational sustainability and increased its commitment to diversity and inclusion.
Quest Diagnostics has successfully acquired Mercy's outreach laboratory services business in an all-cash asset transaction, though financial terms were not disclosed. This acquisition allows Quest to enhance patient care by broadening access to its comprehensive lab services across Arkansas, Kansas, Missouri, and Oklahoma. Mercy will retain ownership of its hospital labs, ensuring continued service for inpatient care. By leveraging Quest's advanced test menu and extensive patient-access network, this deal aims to deliver innovative and cost-effective laboratory solutions to healthcare providers and patients in the Midwest.